Erasmus Medical Center, Cancer Institute, Department of Radiotherapy, Rotterdam, The Netherlands; Holland Proton Therapy Center, Delft, The Netherlands.
Erasmus Medical Center, Cancer Institute, Department of Radiotherapy, Rotterdam, The Netherlands; Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria.
Radiother Oncol. 2022 Jun;171:173-181. doi: 10.1016/j.radonc.2022.04.021. Epub 2022 Apr 27.
To investigate the potential clinical benefit of a two-beam arrangement technique using three-dimensional (3D) imaging of uveal melanoma (UM) patients treated with proton therapy and a dedicated eyeline.
MATERIAL/METHODS: Retrospective CT-based treatment plans of 39 UM patients performed using a single beam (SB) were compared to plans with two beams (TB) optimized for better trade-offs in organs-at-risk sparing. The RBE-weighted prescribed dose was 60 Gy (D = 60 Gy) in four fractions, assuming an RBE of 1.1. Dosimetric findings were analyzed for three patient groups based on tumor-optic nerve distance and UM staging (group GrA: ≤3 mm, T1 T2 UM; GrB: ≤3 mm, T3 UM; GrC: >3 mm, T1 T2 T3 UM). Finally, two schedules were compared on biologically effective dose (BED): both beams being delivered either the same day (TB), or on alternate days (TBalter).
All strategies resulted in dosimetrically acceptable plans. A dose reduction to the anterior structures was achieved in 23/39 cases with the two-beam plans. D was significantly lowered compared to SB plans by 12.4 and 15.4 Gy RBE-weighted median dose in GrA and GrB, respectively. D was reduced by 18.6 and 6.0 Gy RBE-weighted median dose in GrA and GrB, respectively. A cost to the optic nerve was observed with a median difference up to 3.8 Gy RBE-weighted dose in GrB. BED differences were statistically significant for all considered parameters in favor of two beams delivered the same day.
A two-beam strategy appears beneficial for posterior tumors abutting the optic nerve. This strategy might have a positive impact on the risk of ocular complications.
研究使用三维(3D)成像技术对接受质子治疗和专用视线治疗的葡萄膜黑色素瘤(UM)患者的两束排列技术的潜在临床益处。
材料/方法:回顾性分析了 39 例采用单束(SB)治疗的 UM 患者的基于 CT 的治疗计划,并将其与优化了更好的风险器官保护权衡的双束(TB)计划进行了比较。假设 RBE 为 1.1,RBE 加权的规定剂量为 60Gy(D=60Gy),分 4 次给予。剂量学结果根据肿瘤视神经距离和 UM 分期对 3 组患者进行了分析(GrA 组:≤3mm,T1 T2UM;GrB 组:≤3mm,T3UM;GrC 组:>3mm,T1 T2 T3UM)。最后,在生物有效剂量(BED)上比较了两种方案:同时照射(TB)或隔日照射(TBalter)。
所有方案均产生了可接受的剂量学方案。与单束计划相比,双束计划在 23/39 例病例中降低了前部结构的剂量。在 GrA 和 GrB 中,D 的 RBE 加权中位数剂量分别降低了 12.4 和 15.4Gy,与 SB 计划相比显著降低。D 的 RBE 加权中位数剂量分别降低了 18.6 和 6.0Gy,在 GrA 和 GrB 中。在 GrB 中,视神经受到了一定的影响,RBE 加权剂量中位数差异高达 3.8Gy。对于所有考虑的参数,BED 差异均具有统计学意义,且同一天给予两束照射具有优势。
对于后部靠近视神经的肿瘤,双束策略似乎是有益的。这种策略可能对眼部并发症的风险产生积极影响。